Test Price
2,800 AED✅ Home Collection Available
DPYD Gene Dihydropyrimidine Dehydrogenase Deficiency Genetic Test in UAE — 2800 AED
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited next‑generation sequencing. Logistics: VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection available daily 8 AM–11 PM. Clinical Guidance: Telephonic post‑test interpretation by a consultant medical geneticist. Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The DPYD NGS test comprehensively sequences the dihydropyrimidine dehydrogenase gene to detect variants associated with profound enzyme deficiency. Identifying these variants is critical for predicting severe, potentially fatal fluoropyrimidine toxicity (e.g., 5‑fluorouracil, capecitabine) and guiding dose‑reduction strategies in accordance with CPIC guidelines.
| Parameter | Our Test (NGS Advantage) | Closest Alternative (PCR Genotyping) |
|---|---|---|
| Analytical Sensitivity | 99.9% (detects rare/novel variants) | ≤90% (limited to known SNPs) |
| Methodology | Next‑Generation Sequencing (NGS) with full gene coverage and CNV analysis | Allele‑specific PCR for DPYD*2A, *13, etc. |
| Turnaround Time | 3 to 4 weeks (comprehensive interpretation) | 5 to 7 days |
| Clinical Actionability | Full pharmacogenetic profile for precise dose adjustment per CPIC | Partial risk categorisation |
Pre‑Test Requirements
A mandatory genetic counselling session to document pedigree of family members with dihydropyrimidine dehydrogenase deficiency. Provide complete clinical history. Acceptable samples: whole blood (EDTA), extracted DNA, or one drop of blood on FTA card.
Logistics & Processing
Home collection daily 8 AM–11 PM by DHA‑licensed phlebotomist. Samples transported in ISO‑certified cold chain. Price: 2,800 AED. Turnaround: 3–4 weeks. WhatsApp +971 54 548 8731 for scheduling and insurance verification.
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
“DPYD testing is a non‑negotiable safety net before initiating fluoropyrimidine chemotherapy. In my practice, identifying a poor metaboliser has prevented life‑threatening toxicity and enabled safer dose selection. Always integrate genetic results with the patient’s overall clinical status and never alter chemotherapy without the treating oncologist’s direct oversight.”
Medication Advisory
⚠ Do Not Discontinue Prescribed Medication
Abruptly stopping chemotherapy or supportive drugs can lead to disease progression or severe complications. Contact your oncologist before making any changes.
Exclusion Criteria
- Inability to provide informed consent
- Unavailability of prior genetic counselling
- Active hemolytic anaemia
- Sample contamination or insufficient material
- Paediatric patients (<18 years) without parental consent (per UAE Medical Liability Law)
Emergency red flags: unexplained severe diarrhoea, oral mucositis, neutropenic fever, seizures, or hand‑foot syndrome. Seek immediate medical attention.
Patient FAQ & Clinical Guidance
1. What is the purpose of DPYD genetic testing, and who should consider it?
Snippet: The test identifies enzyme‑deficiency variants to prevent life‑threatening fluoropyrimidine toxicity. It is strongly recommended for all patients scheduled to receive 5‑fluorouracil or capecitabine, especially those with a family history of severe drug reactions.
2. How is the test performed, and what sample is required?
Snippet: A simple blood draw, extracted DNA, or a single drop of blood on an FTA card is collected by a DHA‑licensed phlebotomist at your home. The sample undergoes next‑generation sequencing in our ISO‑certified lab; results are ready in 3–4 weeks.
3. How do I interpret my DPYD results, and what actions should I follow?
Snippet: Results classify you as normal, intermediate, or poor metaboliser. Poor metabolisers require significant dose reduction or alternative agents to avoid severe toxicity. Your oncologist will integrate these findings with your overall plan. Never adjust your own medication.
UAE Regulatory & Data Privacy Adherence
All procedures comply with Federal Decree‑Law No. 4 of 2016 on Medical Liability, Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL), and Federal Law No. 2 of 2019 Concerning the Use of ICT in Health Fields. Genetic data is pseudonymised, stored securely, and never shared outside our ISO 9001:2015‑certified facility (Cert. INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | DPYD Gene Dihydropyrimidine Dehydrogenase Deficiency Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3 to 4 weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next‑Generation Sequencing (NGS) – full gene coverage and CNV analysis |
| ICD‑10‑CM Code | Z13.89 (Encounter for screening for genetic disease) |
| LOINC Code | 94213-5 (DPYD gene mutations detected in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Address | License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (DNA Labs UAE) |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians